BACKGROUND: It has been reported that cytomegalovirus (CMV) pp65-specific T cells can protect hematopoietic cell transplant (HCT) recipients from CMV complications. Two candidate CMV peptide vaccines composed of the HLA A*0201 pp65(495-503) cytotoxic CD8(+) T-cell epitope fused to 2 different universal T-helper epitopes (either the synthetic Pan DR epitope [PADRE] or a natural Tetanus sequence) were clinically evaluated for safety and ability to elicit pp65 T cells in HLA A*0201 healthy volunteers. METHODS: Escalating doses (0.5, 2.5, 10 mg) of PADRE or Tetanus pp65(495-503) vaccines with (30 adults) or without (28 adults) PF03512676 adjuvant were administered by subcutaneous injection every 3 weeks for a total of 4 injections. RESULTS: No serious adverse events were reported, although vaccines used in combination with PF03512676 had enhanced reactogenicity. Ex vivo responses were detected by flow cytometry exclusively in volunteers who received the vaccine coadministered with PF03512676. In addition, using a sensitive in vitro stimulation system, vaccine-elicited pp65(495-503) T cells were expanded in 30% of volunteers injected solely with the CMV peptides and in all tested subjects receiving the vaccines coinjected with PF03512676. CONCLUSIONS: Acceptable safety profiles and vaccine-driven expansion of pp65(495-503) T cells in healthy adults support further evaluation of CMV peptide vaccines combined with PF03512676 in the HCT setting. CLINICAL TRIALS REGISTRATION: NCT00722839.
BACKGROUND: It has been reported that cytomegalovirus (CMV) pp65-specific T cells can protect hematopoietic cell transplant (HCT) recipients from CMV complications. Two candidate CMV peptide vaccines composed of the HLA A*0201 pp65(495-503) cytotoxic CD8(+) T-cell epitope fused to 2 different universal T-helper epitopes (either the synthetic Pan DR epitope [PADRE] or a natural Tetanus sequence) were clinically evaluated for safety and ability to elicit pp65 T cells in HLA A*0201 healthy volunteers. METHODS: Escalating doses (0.5, 2.5, 10 mg) of PADRE or Tetanus pp65(495-503) vaccines with (30 adults) or without (28 adults) PF03512676 adjuvant were administered by subcutaneous injection every 3 weeks for a total of 4 injections. RESULTS: No serious adverse events were reported, although vaccines used in combination with PF03512676 had enhanced reactogenicity. Ex vivo responses were detected by flow cytometry exclusively in volunteers who received the vaccine coadministered with PF03512676. In addition, using a sensitive in vitro stimulation system, vaccine-elicited pp65(495-503) T cells were expanded in 30% of volunteers injected solely with the CMV peptides and in all tested subjects receiving the vaccines coinjected with PF03512676. CONCLUSIONS: Acceptable safety profiles and vaccine-driven expansion of pp65(495-503) T cells in healthy adults support further evaluation of CMV peptide vaccines combined with PF03512676 in the HCT setting. CLINICAL TRIALS REGISTRATION: NCT00722839.
Authors: Curtis L Cooper; Heather L Davis; Jonathan B Angel; Mary Lou Morris; Sue M Elfer; Isabelle Seguin; Arthur M Krieg; D William Cameron Journal: AIDS Date: 2005-09-23 Impact factor: 4.177
Authors: J Alexander; J Sidney; S Southwood; J Ruppert; C Oseroff; A Maewal; K Snoke; H M Serra; R T Kubo; A Sette Journal: Immunity Date: 1994-12 Impact factor: 31.745
Authors: A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz Journal: J Clin Invest Date: 1995-01 Impact factor: 14.808
Authors: Andrew W Sylwester; Bridget L Mitchell; John B Edgar; Cara Taormina; Christian Pelte; Franziska Ruchti; Paul R Sleath; Kenneth H Grabstein; Nancy A Hosken; Florian Kern; Jay A Nelson; Louis J Picker Journal: J Exp Med Date: 2005-09-05 Impact factor: 14.307
Authors: Mark Cobbold; Naeem Khan; Batoul Pourgheysari; Sudhir Tauro; Dorothy McDonald; Husam Osman; Mario Assenmacher; Lucinda Billingham; Colin Steward; Charles Crawley; Eduardo Olavarria; John Goldman; Ronjon Chakraverty; Premini Mahendra; Charles Craddock; Paul A H Moss Journal: J Exp Med Date: 2005-08-01 Impact factor: 14.307
Authors: Philip R Krause; Stephanie R Bialek; Suresh B Boppana; Paul D Griffiths; Catherine A Laughlin; Per Ljungman; Edward S Mocarski; Robert F Pass; Jennifer S Read; Mark R Schleiss; Stanley A Plotkin Journal: Vaccine Date: 2013-10-13 Impact factor: 3.641
Authors: Stanley A Plotkin; Dai Wang; Abdel Oualim; Don J Diamond; Camille N Kotton; Sally Mossman; Andrea Carfi; David Anderson; Philip R Dormitzer Journal: J Infect Dis Date: 2020-03-05 Impact factor: 5.226
Authors: Xiuli Wang; ChingLam W Wong; Ryan Urak; Armen Mardiros; Lihua E Budde; Wen-Chung Chang; Sandra H Thomas; Christine E Brown; Corinna La Rosa; Don J Diamond; Michael C Jensen; Ryotaro Nakamura; John A Zaia; Stephen J Forman Journal: Clin Cancer Res Date: 2015-04-02 Impact factor: 12.531
Authors: Corinna La Rosa; Jeff Longmate; Joy Martinez; Qiao Zhou; Teodora I Kaltcheva; Weimin Tsai; Jennifer Drake; Mary Carroll; Felix Wussow; Flavia Chiuppesi; Nicola Hardwick; Sanjeet Dadwal; Ibrahim Aldoss; Ryotaro Nakamura; John A Zaia; Don J Diamond Journal: Blood Date: 2016-10-19 Impact factor: 22.113
Authors: Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452